Nobody applauds a barista for originality. A shot of espresso is good because somebody has already done the same nine seconds, at the same pressure, with the same grind, several thousand times before, and knows exactly what the machine does on a humid morning. Stryker has just made that argument about running one of the largest medical technology companies on earth.
Kevin Lobo is handing over the chief executive seat after a tenure that began in 2012 and reshaped what the company is. Stryker arrived in that decade as a formidable orthopaedics name and leaves it as a hardware business sitting inside the operating theatre itself, with surgical robotics, imaging, instruments and a steady appetite for acquisition. The man taking the seat is Spencer Stiles, the chief operating officer, whose professional history reads less like a career than a long tenancy. Almost all of it has been spent inside the building.
That is the entire story, and it is a more interesting story than it first appears. The reflex of the modern board, when a long-serving chief executive signals the exit, is to go shopping. An outside hire is a narrative. It gives the proxy statement a chapter heading, gives the analysts something to model, and gives the board the comfortable feeling of having conducted a search rather than simply opened a door. Stryker opened the door.
The coffee comparison holds because the failure mode is identical in both directions. Bring in a celebrated roaster from somewhere else and you may get a brilliant new blend, or you may get six months of a visitor learning that this particular grinder runs hot after eleven and the water here is harder than the water there. Promote the person who has stood at the machine through four summers and you forfeit the surprise, but you keep the muscle memory. In a business where the product is inserted into a human being by a surgeon who has to trust it, muscle memory is not a consolation prize.
The insight is about what medtech actually sells. The device is the smallest part of it. What a hospital system buys is a regulatory file that holds up, a supply chain that does not stutter when a port closes, a training programme that gets surgeons comfortable with a new tool, and a sales organisation that has been in that theatre before. None of those are things a new arrival can carry in a briefcase. They are relationships and institutional reflexes, and they live in people who have been there long enough to know which ones matter. A chief operating officer who has spent a career inside the operation is not a safe choice in the apologetic sense. He is a choice about where the company thinks its value is kept.
There is a second reading, which is about the discipline of growing your own. A company only gets to promote from within if it spent the previous decade building people worth promoting. That is slow, unglamorous work with no announcement attached to it, and it is the part of succession planning that gets talked about in every governance seminar and executed in very few boardrooms. Stryker did the unglamorous work and is now cashing it in. The transition announcement is the receipt, not the achievement.
Markets like a story. Boards, on the better days, prefer a working machine. Stryker has just told everyone which of the two it is running, and the answer is that the pressure gauge has not moved, the grind has not changed, and the person now standing at the machine already knows what it does on a humid morning.
Source: Life Science Focus, “Stryker CEO steps down, company veteran takes over”
